Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioTime

This article was originally published in The Gray Sheet

Executive Summary

Grosses $4.6 mil. in secondary offering of 900,000 shares at $5.125. The net proceeds from the offering bring BioTime's cash on hand to about $6 mil., which will be used to support product development and testing programs and an effort "to seek FDA approval of one or more versions of [the firm's] blood substitute and organ-preservation solutions," the company says. The Berkeley, California firm's shares recently began trading on the Boston Stock Exchange under the symbol "BTM," and continue to trade on the NASDAQ exchange under "BTIM" ("The Gray Sheet" Jan. 13, 1992, p. 28)
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002163

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel